Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBR759 dose escalation in CKD patients on hemodialysis
NCT00750295Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2007
- Primary completion
- Jan 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SBR759 in hyperphosphatemia (7 cohorts), sponsored by Novartis. Primary endpoint: Serum phosphorus concentration. Started Feb 2007; status: completed.
02
Drugs
SBR759
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00750295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750295.